Response to letter regarding “Evaluation of the clinical outcome of hypercalcemia of malignancy and concurrent azotemia in dogs with lymphoma”
Journal of Veterinary Internal Medicine · 2024
DOI: 10.1111/jvim.17058 ↗At a glance
Leserbrief in Journal of Veterinary Internal Medicine, 2024. Written by Alyssa A Strumpf and 2 co-authors. Institution: The Ohio State University, College of Veterinary Medicine, Columbus, Ohio, USA. Major MEDLINE topics: Dog Diseases, Hypercalcemia, Azotemia, Lymphoma. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
We appreciate your letter providing specific concerns about our conclusions and the validity of our study. Our study was limited by its retrospective design, but we believe the main conclusion about clinical outcome in this subset of dogs presenting with multicentric intermediate- to high-grade lymphoma, concurrent hypercalcemia, and azotemia was valid and useful for veterinary oncologists. Regarding the first point of contention in validating the diagnosis of an acute kidney injury (AKI), we clearly stated throughout the manuscript the designation of azotemia in this subset of dogs. We were transparent in our decision to classify the azotemia as AKI and the limitations in doing so. As you mentioned, given the retrospective nature of the study, markers of AKI were not evaluated, although evaluation of such markers would be valuable if a prospective study were to be performed. Also, as a consequence of the retrospective design, urine protein-to-creatinine ratios (UPCs) were not available to better support the presence of AKI. We agree that expanding on the urinalysis, specifically protein concentration and sediment examination, would have added value to the manuscript. In discussing the adverse effects of hypercalcemia, specifically related to renal tubular injury and the role of parathyroid hormone-related peptide (PTHrP), we felt there was adequate discussion of this topic for understanding the clinical outcome in dogs affected by this paraneoplastic syndrome. The manuscript focused on the relevant outcomes in dogs with this syndrome and the resulting sequelae, but we could not provide additional information given the retrospective nature of the study and lack of necropsy results. Although there are other mediators of hypercalcemia of malignancy (eg, osteolytic activity, tumor secretion of vitamin D, tumor-associated prostaglandins), PTHrP appears to have important effects on the renal system. We agree that addition of PTHrP data would have added considerable validity to the diagnosis of hypercalcemia of malignancy, but given the retrospective nature of the study, no patients had this test performed at the time of diagnosis. Given the focus on clinical outcomes in our study, we did not address the topic of urine concentration beyond its role in the classification of the azotemia, although we understand the usefulness of this topic. Although we did not elaborate, we did address the difficulty in assessing the extent of prerenal azotemia in our patients, which again arose as a consequence of the study's retrospective design. We were forthcoming about the likelihood of a prerenal component in most of the dogs. We discussed the possibility that dogs with higher serum creatinine concentrations had renal azotemia rather than only prerenal azotemia, but again, we were limited by the retrospective nature of the study. Because azotemia did not fully resolve in some dogs, we hypothesized that renal azotemia could have occurred secondary to the hypercalcemia. It could not however be ascertained whether some dogs in our study had renal impairment before their diagnosis of lymphoma. We did not focus on the supportive care of those dogs hospitalized originally and believe that even if we had included more detail on their hydration status and fluid therapy, it would still be very difficult to determine whether prerenal azotemia existed alone or in conjunction with renal azotemia. As you mentioned in the last 2 paragraphs of your letter, our major conclusions were that treating the underlying lymphoma would resolve the secondary sequelae, and ultimately dogs would not die from the suspected AKI.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- The Ohio State University, College of Veterinary Medicine, Columbus, Ohio, USA.
Cite
APA
Strumpf, A. A., Selmic, L., & Husbands, B. (2024). Response to letter regarding “Evaluation of the clinical outcome of hypercalcemia of malignancy and concurrent azotemia in dogs with lymphoma”. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17058
Vancouver
Strumpf AA, Selmic L, Husbands B. Response to letter regarding “Evaluation of the clinical outcome of hypercalcemia of malignancy and concurrent azotemia in dogs with lymphoma”. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.17058
BibTeX
@article{Strumpf2024,
author = {Strumpf, Alyssa A and Selmic, Laura and Husbands, Brian},
title = {Response to letter regarding “Evaluation of the clinical outcome of hypercalcemia of malignancy and concurrent azotemia in dogs with lymphoma”},
journal = {Journal of Veterinary Internal Medicine},
year = {2024},
doi = {10.1111/jvim.17058}
}
EUVIMED